Close Menu

CHICAGO (GenomeWeb) – Envisagenics, a startup focused on aiding drug discovery by applying artificial intelligence to gene sequences, has closed a $2.4 million seed round of venture capital.

The lead investors are mostly women, including Daniella Kranjac, managing director of Dynamk Capital; Shana Fisher, founder of Third Kind Venture Capital; and Gillian Sandler, of New York biotech investment company Cosine, the firm said. Envisagenics also received funding from Peter Thiel's Breakout Labs and from the New York State Innovation Venture Capital Fund.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.